Novavax up 59% premarket on mystery respiratory virus in China
Vaccine developer Novavax (NASDAQ:NVAX) is up 59% premarket on robust volume in apparent reaction to the spread of an unknown respiratory virus in China that has killed six people to date.
Buying appears to have spread to Inovio Pharmaceuticals (NASDAQ:INO) (+13%) and BioCryst Pharmaceuticals (NASDAQ:BCRX) (+6%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.